Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for FSGS: experimental drug enters Mid-Stage trial

NCT ID NCT07268638

Recruiting now Disease control Sponsor: Akebia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyone can take the drug for another 24 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome focal segmental glomerulosclerosis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigator Site # 1

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

  • Investigator Site #10

    RECRUITING

    Pontiac, Michigan, 48341, United States

  • Investigator Site #11

    RECRUITING

    Louisville, Kentucky, 40205, United States

  • Investigator Site #12

    RECRUITING

    San Dimas, California, 91773, United States

  • Investigator Site #13

    RECRUITING

    Arvada, Colorado, 80002, United States

  • Investigator Site #14

    RECRUITING

    Los Angeles, California, 90022, United States

  • Investigator Site #15

    RECRUITING

    Livonia, Michigan, 48152, United States

  • Investigator Site #16

    RECRUITING

    New Bern, North Carolina, 28562, United States

  • Investigator Site #17

    RECRUITING

    Boca Raton, Florida, 33431, United States

  • Investigator Site #18

    RECRUITING

    Houston, Texas, 48152, United States

  • Investigator Site #19

    RECRUITING

    Bridgeville, Pennsylvania, 15017, United States

  • Investigator Site #2

    RECRUITING

    Chula Vista, California, 91910, United States

  • Investigator Site #20

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Investigator Site #21

    RECRUITING

    Dallas, Texas, 75230, United States

  • Investigator Site #22

    RECRUITING

    Butler, Pennsylvania, 16001, United States

  • Investigator Site #23

    RECRUITING

    Goose Creek, South Carolina, 29445, United States

  • Investigator Site #24

    RECRUITING

    Worcester, Massachusetts, 01608, United States

  • Investigator Site #25

    RECRUITING

    Hialeah, Florida, 33010, United States

  • Investigator Site #3

    TERMINATED

    Chicago, Illinois, 60643, United States

  • Investigator Site #4

    RECRUITING

    Chattanooga, Tennessee, 37404, United States

  • Investigator Site #5

    RECRUITING

    Arlington, Texas, 76015, United States

  • Investigator Site #6

    RECRUITING

    Coral Springs, Florida, 33071, United States

  • Investigator Site #7

    RECRUITING

    Miami, Florida, 33172, United States

  • Investigator Site #8

    RECRUITING

    Orlando, Florida, 32806, United States

  • Investigator Site #9

    RECRUITING

    Dallas, Texas, 75231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.